SCHEMBL13614904

SCHEMBL13614904

c1ccc(-c2ccccc2-c2c3ccccc3c(-c3ccc(-c4nc5ccccc5nc4-c4ccc(-c5c6ccccc6c(-c6ccccc6-c6ccccc6)c6ccccc56)cc4)cc3)c3ccccc23)cc1

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.51
L3MBTL1 Q9Y468 5/20 0.51
KDM4E B2RXH2 5/20 0.51
GAA P10253 2/20 0.51
TDP1 Q9NUW8 2/20 0.51
MEN1 O00255 1/20 0.51
KMT2A Q03164 1/20 0.51
ALDH1A1 P00352 3/20 0.51
NPSR1 Q6W5P4 1/20 0.47
AKT1 P31749 1/20 0.45
AKT2 P31751 1/20 0.45
PKM P14618 1/20 0.44
ESR1 P03372 2/20 0.44
ESR2 Q92731 2/20 0.44
THRB P10828 1/20 0.43
ADORA2A P29274 1/20 0.42
NUDT1 P36639 1/20 0.42
DHODH Q02127 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1766036 0.89 L3MBTL1 (0.62) LMNAL3MBTL1KDM4EGAATDP1
SCHEMBL22470183 0.89 L3MBTL1 (0.62) LMNAL3MBTL1KDM4EGAATDP1
SCHEMBL13614893 0.88 L3MBTL1 (0.60) LMNAL3MBTL1KDM4EGAATDP1
SCHEMBL24433114 0.86 CYP11B1 (0.48) LMNAL3MBTL1KDM4EGAATDP1
SCHEMBL26460809 0.84 LMNA (0.47) LMNAL3MBTL1KDM4EGAATDP1
SCHEMBL24689392 0.84 KDM4E (0.64) LMNAL3MBTL1KDM4EGAATDP1
SCHEMBL5442446 0.84 ACHE (0.43) LMNAL3MBTL1KDM4ETDP1ALDH1A1
SCHEMBL14228010 0.83 L3MBTL1 (0.44) LMNAL3MBTL1KDM4EGAATDP1
SCHEMBL25957743 0.82 ACHE (0.45) LMNAL3MBTL1KDM4ETDP1ALDH1A1
SCHEMBL24433143 0.81 CYP11B1 (0.49) LMNAL3MBTL1KDM4EGAATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7612204-B2 Quinoxaline derivative, and light-emitting element and light-emitting device using quinoxaline derivative SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2009-11-03 US disclosed
US-7612204-B2 Quinoxaline derivative, and light-emitting element and light-emitting device using quinoxaline derivative SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2009-11-03 US disclosed
US-20080091012-A1 Quinoxaline Derivative, And Light-Emitting Element And Light-Emitting Device Using Quinoxaline Derivative SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2008-04-17 US disclosed
US-20080091012-A1 Quinoxaline Derivative, And Light-Emitting Element And Light-Emitting Device Using Quinoxaline Derivative SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2008-04-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080091012-A1 Quinoxaline Derivative, And Light-Emitting Element And Light-Emitting Device Using Quinoxaline Derivative NQO1, GLB1, PDXK LMNA 3244/4885L3MBTL1 1370/4885KDM4E 2134/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.